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1. Introduction 
Squamous cell carcinomas of the head and neck are a biologically heterogeneous group of 
cancers with a variable clinical course (Tran et al., 2007). 
Human tumor viruses account for approximately one-fifth of all cancers worldwide 
(Psyrri & Tsiodoras, 2008). The first association between human papillomavirus and  
head and neck cancer was observed during the 1960s (Rabbett, 1965). A possible role for 
human papillomavirus in the etiology of cancers at other sites within the head and neck 
was first suggested by Löning et al., in 1985. Since then, mounting epidemiological, 
molecular, and clinical evidence indicates that high-risk human papillomavirus 
(especially human papillomavirus-16) account for the development of head and neck 
carcinoma in some individuals who do not have the classical risk factors for this disease 
(Psyrri & Dimaio, 2008).  
Distinguishing human papillomavirus positive from human papillomavirus negative 
head and neck squamous cell carcinoma can provide prognostic information, because 
different studies have shown better clinical outcome among patients with human 
papillomavirus positive head and neck squamous cell carcinoma. Although there are 
innumerable options for human papillomavirus detection in head and neck squamous cell 
carcinoma, there isn´t any standardization of procedures to use in clinical practice. Several 
authors propose a testing algorithm of first screening for human papillomavirus using 
p16 immunohistochemistry, after positive p16 results confirmatory testing with 
polymerase chain reaction  or similar technique is carried out (Pannone et al., 2012; 
Smeets et al., 2007). 
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The demonstration that human papillomavirus have a role in human carcinogenesis has 
allowed the development of preventive and therapeutic strategies aimed at reducing the 
incidence and mortality of human papillomavirus-associated cancers (Psyrri & Dimaio, 
2008). 
This chapter reviews the human papillomavirus detection in head and neck squamous cell 
carcinoma and its clinical implications. Our search strategy included an electronic search of 
MEDLINE (pubmed), to identify all published articles about this issue. We use the key 
words “Human papillomavirus”, “head and neck neoplasm”. We checked the titles and 
abstracs retrieved. Each author independently assessed the full text of studies relevant to 
this review. 
2. Risk factors in head and neck cancer 
The main risk factors for head and neck cancer globally are tobacco and alcohol (Dobrossy, 
2005). These agents act by inducing mutations in key genetic pathways that govern normal 
cell turnover such as p53 and the product of the retinoblastoma gene (pRb) (Pfeifer et al., 
2002)(figure1).  
Approximately 20% of head and neck cancers occur in people lacking these established 
risk factors (Wiseman et al., 2003). There is strong epidemiologic and experimental 
evidence indicating that human papillomavirus accounts at least partly for this subset of 
cancers (Shanta et al., 2000), and it has suggested that human papillomavirus may be an 
independent risk factor for oropharyngeal carcinoma, as well as a modulator the 
malignancy process in some tobacco-and alcohol-induced oropharynx tumors (Turner et 
al., 2011). 
 
 
Figure 1. Inactivation of p53 and pRb by mutation by carcinogen agents. The p53 tetramers induce the 
expression of p21, which inhibits (dotted line) several cyclins. These cyclins induce the 
hyperphosphorylation of Rb, which normally binds to and inactives the E2F. The hyperphosphorylated 
form prevents the binding of E2F, which can then initiates uncontrolled cell division. 
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2.1. Human papillomavirus: Concept 
Human papillomavirus is a member of the papillomaviridae family. They are small, non-
enveloped, DNA viruses. They may be found integrated into the host genome, non-
integrated or episomal, or as a combination or mixture of these types in infected tissue 
(Turner et al., 2011) [figure 2].  
Mucosal human papillomavirus can be categorized in 2 major groups based on oncogenic 
potential: “low-risk” and “high-risk”. Human papillomavirus 16 and 18 are the major ‘‘high-
risk’’ types, which are associated with precancerous lesions (Tran et al., 2007; Psyrri  
Tsiodoras, 2008; Psyrri & Dimaio, 2008; Snow & Laudadio, 2010). 
 
 
Figure 2. DNA viruses (dotted) and the host genome 
2.2. Human papillomavirus life cycle and its role in the pathogenesis of head 
and neck squamous cell carcinoma (head and neck squamous cell carcinoma) 
Through wounds or abrasions, the papillomaviruses infect basal epithelial cells. The viral 
DNA is maintained in the nuclei of infected epithelial cells (Stubenrauch & Laimins, 1999). 
human papillomavirus-DNA replicates to a high copy number only in terminally 
differentiated cells near the epithelial surface (Stubenrauch & Laimins, 1999). The late viral 
genes, which encode the L1 and L2 proteins that constitute the virus particle, are expressed 
only in the highly differentiated cells (Bedell et al., 1991). 
Replication of the human papillomavirus genome is critically dependent on the host-cell 
DNA replication machinery (Cheng et al., 1995). The papillomavirus E1 and E2 proteins are 
required for viral DNA replication and papilloma formation (Wu et al., 1994). E1 is an ATP-
dependent helicase that initiates viral replication in cooperation with the E2 protein. In 
addition, the E2 protein can function as a transcriptional repressor of E6 and E7 oncogene 
expression among other functions (Psyrri & Dimaio, 2008). E2 loss of function allows up-
regulation of E6 and E7 oncoproteins (Pannone et al., 2012).  
Transcription of human papillomavirus-16 E6/E7 mRNA in tonsillar carcinomas is not 
necessarily dependent on viral DNA integration, and the viral DNA is predominately in 
episomal form (Mellin et al., 2002). It has been also demonstrated that high risk human 
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papillomavirus episomal DNAs up-regulate the activity of E6/E7 promoter, which in turn 
gives rise to elevated E6 and E7 protein expression in cancer cell (Pannone et al., 2012). 
Mellin et al (Mellin et al., 2002) concluding that in oropharyngeal carcinomas human 
papillomavirus is almost exclusively not integrates and its carcinogenic activity is due to 
E6/E7 oncoproteins expressed from episomal viral sequences. It is unknown whether the 
physical state of the virus influences tumor biology (Tran et al., 2007; Koskinen et al, 2003). 
However, the data suggested that a higher viral load cloud be a favourable prognostic 
indicator and that tumours with episomal DNA had larger tumours than patients with 
mixed or integrates forms of viral DNA. Higher copy number of episomal viral DNA was 
able to induce more rapid growth, perhaps by higher expression of the viral oncogenes 
(Pannone et al., 2011). 
Human papillomavirus encode E6 and E7 proteins that create a state competent for DNA 
replication. The E6 protein of the high-risk human papillomavirus binds and induces the 
degradation of the p53 tumor suppressor protein via an ubiquitin-mediated process. E6 also 
activates telomerase allowing the regenesis of the ends of chromosomes after cell division. 
While, the human papillomavirus-E7 protein binds and destabilizes the retinoblastoma (Rb) 
tumor suppressor protein and related proteins. The molecular consequence of the 
expression of these viral oncoproteins is cell cycle entry and inhibition of p53-mediated 
apoptosis (figure 3). The E6 and E7 proteins also interact with other cellular targets. 
Together, these effects promote cell-cycle progression and viral DNA replication in 
differentiated keratinocytes (Tran et al., 2007; Leemans et al., 2011; Hobbs et al., 2006). 
 
Figure 3. Inactivation of p53 by E6, inactivation of pRb by E7, and p16 over-expression. The E6 protein 
binds p53 and targets the protein for degradation, whereas the E7 protein binds and inactivates the Rb 
protein. pRB family proteins negatively regulate p16 gene expression. When E7 binds to pRB, this 
protein is inactivated, thus, p16 expression increase. Although p16 levels rise, normal feedback is by-
passed, as human papillomavirus (HPV)-mediated cell proliferation is not dependent on 
cyclinD/Cdk4/6 (Dotted line = inhibition) 
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As a result, somatic mutation in TP53 (encoding p53), cyclin D1, and deletion or silencing 
CDKN2A (encoding p16) are established cancer genes in human papillomavirus-negative 
head and neck squamous cell carcinoma. In contrast, human papillomavirus-associated 
tumors are less likely to harbor TP53 mutation and the genes encoding the Rb family are 
established cancer genes in human papillomavirus-positive head and neck squamous cell 
carcinoma. In addition, human papillomavirus-positive head and neck squamous cell 
carcinoma has strong expression of p16 (as a component of the retinoblastoma tumor 
suppressor pathway) (Snow & Laudadio, 2010; Leemans et al., 2011). In the other hand, p16 
expression loss defines a subgroup of head and neck squamous cell carcinoma patients with 
human papillomavirus-negative tumors. 
So, the etiology of head and neck cancer is complex. Human papillomavirus, tobacco and 
alcohol represent three independent risk factors for head and neck carcinoma in the oral 
cavity and oropharynx. 
The different risk factors can be combined. Smith et al (Smith et al., 2012) found that cancer 
in oral cavity or oropharyngeal risk was different among patients with several risk factors 
(Table 1). This investigation suggests that while risk of head and neck squamous cell 
carcinoma by tumor site is both different between oral cavity and oropharynx, both sites are 
nonetheless associated with independent effects for each of the three major head and neck 
squamous cell carcinoma risk factors. 
The association between tobacco/alcohol, human papillomavirus, and tumor site is complex. 
 
Oral Cavity/Oropharynx 
Human papillomavirus-
positive 
Human papillomavirus-negative 
Heavy alcohol user OR=3,5/OR=4,7 OR=1,4/OR=11 
Heavy tobacco user OR=9,8/OR=8,5 OR=3,1/OR=24,3 
Table 1. Risk of oral cavity and oropharyngeal carcinoma (Smith et al., 2012). OR=Odds Ratio 
3. Epidemiologic and experimental evidence of an etiologic role for 
human papillomavirus in head and neck squamous cell carcinoma 
Certain subsets of head and neck squamous cell carcinoma have fallen in parallel with the 
reduction in smoking, rates of oropharyngeal squamous cell carcinomas have risen by 2.1% 
and 3.9% among men and women respectively, from 1973 to 2001, particularly tongue and 
tonsillar cancers (Shiboski et al., 2005). Similarly, the incidence of tonsillar cancer increased 
by approximately 2–3% per year among men younger than 60 years from 1975 through 1998 
(Canto & Devesa, 2002). In addition, the incidence of human papillomavirus-associated 
oropharyngeal cancer has increased between 1973 and 2004 (Chaturvedi et al., 2008).  
These data suggest that human papillomavirus has emerged as an increasingly important 
cause of oropharyngeal cancer not only because tobacco-associated head and neck 
squamous cell carcinoma have decreased, but also because the incidence of human 
papillomavirus-associated oropharyngeal cancer is increasing (D´Souza & Dempsey, 2011). 
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This increase in the incidence of oropharyngeal cancer was paralleled by an increase in 
certain sexual behaviors. This change in the demographics of patients with head and neck 
squamous cell carcinoma is consistent with a role for genital human papillomavirus in the 
pathogenesis of oropharyngeal squamous cell carcinoma in individuals whose sexual 
practices are typically associated with sexual transmission of the virus (Psyrri & Dimaio, 
2008). An elevated risk of oropharyngeal cancer has been associated with increasing number 
of sexual partners, younger age of first sexual intercourse, the practice of oral sex, and a 
history of genital warts (Trans et al., 2007). 
One of the most important studies establishing the causal relationship between human 
papillomavirus and head and neck cancer was a multi-center case control study conduced 
by the International Agency for Research into Cancer (IARC) (Herrero et al., 2003). Findings 
confirmed that human papillomavirus-positive tumors cluster among non-smokers and 
nondrinkers. 
There has been wide variation in human papillomavirus positivity rates in cancers at 
different sites within the head and neck. Approximately 25% of oropharyngeal cancers have 
tested human papillomavirus-positive, with rates in tonsillar cancer considerably higher 
(Trans et al., 2007). In fact, tonsillar crypts seem particularly susceptible to transformation by 
human papillomavirus, which is similar to the transformation zone of the uterine cervix, the 
location in which most cervical cancers originate (Psyrri & Dimaio, 2008). 
4. Human papillomavirus detection 
Since Syrjänen´s initial observations in 1983 (Syrjänen et al., 1983), there have been 
numerous reports on human papillomavirus-DNA detection in head and neck squamous 
cell carcinoma with rates varying from 0% to 100% of tumors studied (Clifford et al., 2003; 
Campisi et al., 2007). These differences in detection rate are due to at least two principal 
factors (Pannone et al., 2012): 
1. Differences in the epidemiological distribution of oncogenic high risk human 
papillomavirus in the world 
2. Different analytical methods utilized 
So, there are nearly innumerable options for human papillomavirus detection in head and 
neck squamous cell carcinoma and no standardization of procedures to be used in clinical 
practice. The method choice depends greatly upon the desire information (test directed at 
identifying a broad group of high risk human papillomavirus or targeted at specific human 
papillomavirus genotypes), available tissue type (fresh tissue, fixed tissue, incision biopsy, 
brush cytology, saliva, serum, fine needle aspiration biopsy), the ubiquity and preservation 
of the candidate target molecule (DNA, RNA, and protein), and resources in (Snow & 
Laudadio, 2010; Robinson et al., 2010) 
The Southern blot has long been considered the gold standard for detection of specific DNA 
sequence, however, with its technical demand, necessity for large quantities of DNA… Its use 
in clinical applications for human papillomavirus detection is rare (Snow & Laudadio, 2010). 
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Several amplification techniques (polymerase chain reaction [PCR]) have been developed 
for human papillomavirus type–specific using a specific primer set or for wide-spectrum 
human papillomavirus detection. Some of them adequately and equivalently amplify the 
target of interest, as L1 (late gene that encodes the viral capsid). However, multiple portions 
of the human papillomavirus genome, including L1, may be deleted in the process of 
integration to false negative results. For this reason, assays have been developed, which 
amplify portions of E6 and E7 (Snow & Laudadio, 2010). Many studies have shown 
reproductible results and high sensitivity with RNA-based assays (reverse transcriptase 
polymerase chain reaction) when using frozen tissue, but this material is not always available 
for testing. Multiple studies have compared RNA extraction from fresh or frozen tissue with 
that from formalin-fixed-paraffin-embedded tissue. The greatest decrease in RNA quality 
occurs immediately after fixation and processing (Snow & Laudadio, 2010).  
Consensus polymerase chain reaction and genotyping is applicable to formalin-fixed-paraffin-
embedded material and it has high sensitivity, however, it can detect of biologically irrelevant 
human papillomavirus, and the sample can be contaminated during biopsy acquisition. Type 
specific polymerase chain reaction has similar characteristics to consensus polymerase chain 
reaction. Real time polymerase chain reaction is applicable to formalin-fixed-paraffin-embedded 
material, it has high sensitivity and specificity, and it gives an estimate of the viral load, 
however, it requires tissue microdisecction and DNA extraction (Robinson et al., 2010). 
The human papillomavirus-DNA test may be used in head and neck pathology departments 
with the following diagnostic and prognostic purposes (Reimers et al., 2007): 
1. Distinguish human papillomavirus positive from human papillomavirus negative head 
and neck squamous cell carcinoma and providing prognostic information 
2. Distinguish human papillomavirus positive metastases to the loco-regional lymph 
nodes derived from oropharyngeal cancers versus metastases of other origins 
3. Furnish potentially useful indications for cancer treatment options 
4. Contribute to the differential diagnosis of rhino-pharynx undifferentiated carcinoma 
(Worl Health Organization type I potentially related to human papillomavirus infection 
whereas Type II and III potentially related to Epstein Barr Virus) 
5. Provide valuable information for head and neck cancer research 
Table 2 shows the different types of primers (Hunsjak et al., 2000; Gravitt et al., 2003; Snow 
& Laudadio, 2010; Micalessi et al., 2012). Figure 4 shows the genomic structure of human 
papillomavirus. 
Immunohistochemistry for the expression of viral human papillomavirus proteins as p16, 
E5, E6, E7 as surrogate markers of human papillomavirus infection. In the case of p16, 
human papillomavirus independent pathways of oncogenesis can lead to increased 
expression of p16 and the specificity is only 79% (Snow & Laudadio, 2010; Pannone et al., 
2011). In fact, the immunohistochemistry detection of p16 protein has been proposed as 
surrogate marker of human papillomavirus infection in head and neck squamous cell 
carcinoma (Reimers et al., 2007). 
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Figure 4. Genomic structure of human papillomavirus 
 
Consensus 
Target: L1 
Degenerated Not degenerated Advantages: They have a larger 
spectrum of  human papillomavirus  
detection. 
Disadvantages: during the 
integration into the host DNA, parts 
of the L1 region may be deleted, 
contributing to false negative results. 
SPF: it has higher sensitivity 
compares to MY and GP because of 
its shorter amplification product (65 
base pairs). 
MY09, MY11 
(450 base pairs) 
GP5+, GP6+ 
(140 base pairs) 
SPF 
(65 base pairs) 
Specific 
Target:  
(for example: 
E6/E7) 
Polymerase chain reaction directed 
at a single  human papillomavirus 
The use of several specific primer 
pairs combined is called multiplex 
reaction 
Advantages: they are available for 
target detection and type 
discrimination. 
Disadvantages: they require a 
polymerase chain reaction for each 
human papillomavirus type. 
Multiplex primer sets are directed at 
high or low-risk, but not specific  
human papillomavirus . 
Table 2. Different types of primers.  
In situ hybridization is a reproducible technique applicable to detection of a wide of human 
papillomavirus types particularly from formalin-fixed-paraffin-embedded tissues. However, 
in situ hybridization is considered method with a low sensitivity, because the low 
applicability in clinical routine for the long and hard technical word required in (Snow & 
Laudadio, 2010; Pannone et al., 2011). 
A recent study (Pannone et al., 2012) has tested the reliability of a triple method which 
combines evaluation of p16 expression of viral human papillomavirus proteins by 
immunohistochemistry, human papillomavirus-DNA genotyping by polymerase chain 
reaction, and viral integration into the host by in situ hybridization. All the head and neck 
LCR
L1
E6 E7
E1
E2
E4
E5 
L2
HPV 
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squamous cell carcinoma confirmed human papillomavirus positive by polymerase chain 
reaction and/or in situ hybridization were also p16 positive by immunohistochemistry. So 
immunohistochemistry showed a very high level of sensitivity as single test but lower 
specificity level. The double method, in situ hybridization and polymerase chain reaction 
increased significantly the specificity, but reduced the sensitivity. They observed different 
levels of p16-immunohistochemistry accuracy in the different cancer subpopulation studied. 
So, in a cohort of prevalently alcohol/tobacco associated cancers, p16-immunohistochemistry 
test showed a lower level of specificity in detecting human papillomavirus positive cases. In 
addition, a recent literature report demonstrates different p16 accuracy according to 
different anatomical sub-sites of head and neck region (Doxtader & Katzenstein, 2011). In 
this context, the p16-immunohistochemistry test alone could be used only as a screening 
method and need to be associated with molecular tests in order to detect human 
papillomavirus-DNA and to assess its integration status. 
The hybrid capture technique is used extensively among pathology labs to detect 13 high-
risk human papillomavirus genotypes in cervical cytology specimens. The use of this 
method is limited for head and neck squamous cell carcinoma human papillomavirus 
testing, but the technique has potential for screening oral brushings. However, at this time, 
oral brush cytology has not achieved a sensitivity or specificity sufficiently competitive with 
surgical biopsy for diagnosis and prospective studies are necessary to determine the clinical 
use of screening in (Snow & Laudadio, 2010; Pannone et al., 2011). 
Luminex system combines PCR with hybridization to fluorescence-labeled polystyrene 
bead microarrays. This technology provides a new platform for high-throughput nucleic 
acid detection and is being utilized with increasing frequency. It is a sensitive, 
reproducible technique for the simultaneous genotyping of all clinically relevant genital 
HPV types. However, these Luminex assays have shown low ability for type-specific 
genotyping and have missed variants with the type-specific probes. Multiple infections 
may occur in 20-40% of specimens. Luminex-based HPV genotyping can be used to 
differentiate between newly acquired HPV types and pre-existing infections when applied 
over time. Nevertheless, a limitation of the assay is the reduction of signal that occurs for 
a plasmid target in low abundance when it is amplified with another target that is 2 or 3 
logs higher in abundance. This technology has been tested in cervical samples (Oh et al., 
2007; Lowe B et al., 2010). 
Human papillomavirus serology. The immune to human papillomavirus infection involves 
both the cell-mediated and humoral responses. Human papillomavirus seropositivity is 
potentially indicative not only of current oral infection but also of any past infection not 
limited to the oral cavity or oropharynx (Pannone et al., 2011). Antibodies to human 
papillomavirus E6 and E7 proteins are markers for an invasive human papillomavirus-
associated cancer. The use of human papillomavirus viral load in conjunction with 
serological markers may serve to identify a subset of human papillomavirus-associated head 
and neck tumors in which human papillomavirus is biologically active (Ragin et al., 2007). 
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Table 3 resumes the characteristics of different methods for human papillomavirus detection 
(Dobrossy, 2005). 
 
Method Detect Characteristics Sample 
Southern Blot 
Specific DNA 
sequence 
It needs large quantities of 
DNA. It don´t use in clinical 
practice. Low sensitivity 
Frozen tissue 
Polymerase chain 
reaction 
Amplify particular 
DNA sequence 
There are several sets. 
- Consensus polymerase chain 
reaction: high sensitivity, but it 
can detect biological irrelevant 
human papillomavirus. 
- Type specific polymerase chain 
reaction: as above 
- Real time polymerase chain 
reaction: high sensitivity and 
specificity, but it requires tissue 
microdissection and DNA 
extraction 
- Reverse transcripase polymerase 
chain reaction: high sensitivity 
and specificity, but adequate 
performance is limited to frozen 
tissue 
Formalin-fixed-
paraffin-
embedded 
More accuracy in 
fresh frozen 
tissue for reverse 
trancriptase 
Polymerase chain 
reaction 
Immuno- 
histochemistry 
Viral human 
papillomavirus 
proteins 
High sensitivity in screening. 
Specificity is low. 
Formalin-fixed-
paraffin-
embedded 
In situ 
hybridization 
Specific DNA or 
RNA sequence 
It has a low sensitivity 
Formalin-fixed-
paraffin-
embedded 
Hybrid Capture 
High-risk human 
papillomavirus 
genotypes 
It has potential for screening 
oral brushing. Lower sensitivity 
and specificity than surgical 
biopsy 
Oral brush 
cytology 
Serology 
Cell-mediated and 
humoral responses
Minimally invasive test. 
It indicates human 
papillomavirus infection but not 
limited to the oral cavity or 
oropharynx. 
Low sensitivity and specificity.
Blood 
Table 3. Characteristics of different methods for human papillomavirus detection 
 
Human Papillomavirus Detection in Head and Neck Squamous Cell Carcinomas and Its Clinical Implications 11 
Establishing a diagnosis of head and neck cancer requires the acquisition of adequate biopsy 
material. Typically, tissue samples are fixed in formalin, processed in the laboratory and 
formalin-fixed-paraffin-embedded, whereas fine needle aspiration biopsy samples are 
usually treated with an alcohol-based fixative. So, for an human papillomavirus test to be 
useful it should be capable of reliably classifying ‘human papillomavirus related’ cancers in 
fixed cell and tissue samples. The techniques used should be reproducible, subject to 
standardization and quality assurance and be economically viable (Robinson et al., 2010). 
The presence of the viral DNA does not establish causality, since the majority of human 
papillomavirus infections may be transient rather than persistent (Ragin et al., 2007). The 
important issue is that human papillomavirus is transcriptionally active (Trans et al., 2007; 
Hobbs et al., 2006). In fact, cases that are human papillomavirus positive but negative for 
p16 expression (or negative for E6/E7 mRNA) are molecularly more similar to human 
papillomavirus negative cases suggesting that in these instances human papillomavirus is 
not directly involved in carcinogenesis (Snow & Laudadio, 2010; Weinberger et al., 2006). 
Detection of high-risk E6/E7 mRNA or protein would be the ideal test for classifying a 
tumor as truly human papillomavirus-associated, while it´s possible to perform quantitative 
polymerase chain reaction on formalin-fixed-paraffin-embedded samples the maximum 
accuracy is found using fresh frozen tissue (Pannone et al, 2012). Determination of p16 
expression status by immunohistochemistry could serve as a reasonable surrogate marker 
for biologically relevant high-risk human papillomavirus infection (Psyrri & Dimaio, 2008).  
Smeets et al (Smeets et al., 2007) propose a testing algorithm of first screening for human 
papillomavirus using p16 immunohistochemistry, after positive p16 results confirmatory 
testing with polymerase chain reaction is carried out. This approach had almost 100% 
sensitivity and specificity, with 2% risk of false positive. Others authors as Westra (Westra, 
2009) propose confirmatory testing by in situ hybridization (Robinson et al., 2010). The 
majority of pathology laboratories have the capability of delivering the first algorithm. 
Some authors are searching for other defining molecular characteristics. There is evidence 
that human papillomavirus positive head and neck squamous cell carcinoma tends to 
contain normal copies of the p53 gene (Braakhuis et al., 2004). However, p53 mutations have 
been described in these tumours (Westra et al., 2008). This presence of mutant p53 along 
with human papillomavirus infection in the same tumour raises the possibility that human 
papillomavirus infection is simultaneous and has no influence on pathogenesis (Robinson et 
al., 2010). Human papillomavirus viral oncoproteins are known to have epigenetic effects. 
They can silence the expression of key tumour suppressor genes by promoter methylation 
(Henken et al., 2007). The emergence of global genome methylation assays represents novel 
ways of refining the molecular classification of head and neck cancers in the future 
(Robinson et al., 2010). 
5. Clinical implications 
Several lines of clinical evidence also suggest that human papillomavirus-associated head 
and neck squamous cell carcinoma could be biologically distinct from classical head and 
neck squamous cell carcinoma (Table 4). 
 
Histopathology – Reviews and Recent Advances 12 
CHARACTERISTICS 
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 TP53 y RB1 Inactivation Mutation 
p16   
Cyclin D1 ↓ ↑ 
Histological grading 
↑ Poorly differentiated 
tumours 
Any 
Histotype Often basaloid Basaloid uncommon 
C
L
IN
IC
A
L
 Sex ♂ y ♀ [or ♂ > ♀] ♂ > >♀ 
Age Younger [< 40 yrs] Older 
Tobacco y alcohol Generally NO Generally YES 
Stage at diagnosis Advanced and Later Earlier 
Prognostic Better Worse 
Table 4. Molecular & clinical characteristics in human papillomavirus + and human papillomavirus - 
head and neck squamous cell carcinoma 
Several experiments delineated three biologically and clinically distinct types of 
oropharyngeal tumors (Weinberger et al., 2006) (Table 5):  
 
 
HUMAN PAPILLOMAVIRUS
Negative Positive 
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No Class I Class II 
Yes Class IV Class III 
Table 5. Biologically and clinically distinct types of oropharyngeal tumors 
 Class I, human papillomavirus-negative/p16 non expressing. Conventional head and 
neck squamous cell carcinoma with no evidence of human papillomavirus infection, 
typically exhibiting inactivation of p16, with p53 mutations and probably caused by 
tobacco and alcohol abuse. 
 Class II, human papillomavirus-positive/p16 non expressing. Conventional head and 
neck squamous cell carcinoma that acquire simultaneous human papillomavirus 
infection late in its pathogenesis, with no consequences for p16 expression 
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 Class III, human papillomavirus-positive/ p16 expressing. “human papillomavirus 
related” head and neck squamous cell carcinoma that contains human papillomavirus 
DNA and shows evidence of oncogenic human papillomavirus protein expression, 
using p16 as a surrogate marker. 
 Class IV, human papillomavirus-negative/p16 expressing. Small number of apparently 
human papillomavirus negative carcinomas that over express p16. There are two major 
reasons for this entity: a] misclassification as human papillomavirus negative, because 
the human papillomavirus test chosen lacks sensitivity, b] tumours where accumulation 
of p16 has been caused by perturbation of other cellular signaling pathways, or due to 
possible an as yet unidentified infectious agent.  
Class III had the highest viral loads. The 5-year survival in class III was 79%, significantly 
higher than in the other two classes (20% and 18%, P = 0.0095). Disease free survival for class 
III was 75% compared with 15% and 13% for classes I and II, respectively (P = 0.0025). The 5-
year local recurrence was 14% in class III compared with 45% and 74% (P = 0.03). 
Multivariate survival analysis confirmed the prognostic value of the three class model. It is 
clear that head and neck squamous cell carcinoma human papillomavirus-positive and p16 
expressing is different from classic head and neck squamous cell carcinoma, but it is not 
clear whether head and neck squamous cell carcinoma human papillomavirus-positive and 
p16 non expressing (probably, tobacco/alcohol-related tumors that are infected by high-risk 
human papillomavirus) represents a group biologically distinct from human 
papillomavirus-negative tumors (Cheng et al., 1995).  Other studies in (Smith et al., 2012; 
Harris et al., 2011) have confirmed better disease-specific and recurrence-free survival in 
human papillomavirus and/or p16 positive tumors. 
About class IV, several studies (Reimers et al., 2007; Harris et al., 2011; Shah et al., 2009; 
Weinberger et al., 2004) have shown that patients with human papillomavirus negative and 
p16 positive tumors had better outcomes than patients with p16 negative tumors. So, p16 
status could be the truly important prognostic marker in head and neck squamous cell 
carcinoma, independent of human papillomavirus infection. 
For all this, p16 positivity has been proposed to be a more reliable and reproducible 
prognostic marker in head and neck squamous cell carcinoma (Harris et al., 2011). 
On the basis of these results, we can refine a model for human papillomavirus-associated 
oropharyngeal cancer. The favorable outcome of human papillomavirus-induced 
oropharyngeal cancers might be attributable to the absence of field cancerization or 
enhanced radiation sensitivity (Lindel et al., 2001). In 1953, the term “field cancerization” 
was proposed to explain the high propensity to develop local recurrence after treatment of 
head and neck squamous cell carcinoma and the high likehood that multiple independent 
tumours will develop in the head and neck mucosa. This phenomenon is due to the 
presence of carcinogen induced early genetic changes in the epithelium from which multiple 
independent lesions arise (Slaughter et al., 1953).  
Disrupting E6 and E7 in oropharyngeal cell lines results in increased levels of p53 and pRB 
and increased levels of p53-activated genes (Rampias et al., 2009). These findings indicate 
that in human papillomavirus-induced carcinoma the p53 and pRB pathways remain intact. 
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So, unlike tobacco associated oropharyngeal cancers that harbor mutant TP53, the apoptotic 
response of human papillomavirus-associated tumors to radiation and chemotherapy might 
be intact. Some authors have proposed that p16-expressing cells are less hypoxic and 
respond with less accelerated repopulation when irradiated (Lassen et al., 2009).  
Given that the rate of p53 mutation is quite low in human papillomavirus-associated 
tumors, the addition of p53 mutation sequencing could have added valuable information 
had sufficient tissue been available (Harris et al., 2011). There have been conflicting data on 
p53 expression in human papillomavirus positive head and neck squamous cell carcinoma 
tumor cells.  Some studies have observed high expression of nuclear p53 in some human 
papillomavirus-containing tumors with wild-type p53 (Hafkamp et al., 2003), and other 
studies demonstrating low p53 expression (Wilczynski et al., 1998). Mechanism of over-
expression of wild-type p53 in the presence of the virus is known (Tang et al., 2011). 
It has been suggested that less intensive treatment modalities should be examined in order 
to decrease treatment-toxicities. For that, the National Comprehensive Cancer Network 
Clinical Practice Guidelines in Oncology (USA) (Pfister et al., 2011) recommend that 
oropharyngeal squamous cell carcinoma is tested for high risk oncogenic human 
papillomavirus. 
Furthermore, epidermal growth factor receptor expression has been suggested to be 
correlated with human papillomavirus status (Almadori et al., 2001). There are data 
suggesting a direct link between human papillomavirus-encoded proteins and epidermal 
growth factor receptor expression (Kim et al., 2006). Kumar et al (Kumar et al., 2008) 
reported the phenotype human papillomavirus positive and epidermal growth factor 
receptor high to be associated with poorer survival after chemotherapy and radiation than 
human papillomavirus positive and epidermal growth factor receptor low tumors. 
Bonner et al (Bonner et al., 2010) tested the combination of cetuximab, a monoclonal 
antibody directed against epidermal growth factor receptor, and radiotherapy in head and 
neck squamous cell carcinoma. They demonstrated improved patient survival compared 
with radiation alone. The use of this combination increased skin irritation, but otherwise it 
had the same side effects as radiotherapy alone. An analysis of patients in this trial revealed 
that those with oropharyngeal squamous cell carcinoma who were male and younger, a 
group that mirrors the human papillomavirus-positive population, benefited most from the 
combination therapy. These results suggested that radiation plus cetuximab, instead of 
cisplatin-based chemotherapy, may reduce treatment toxicity without compromising cancer 
control for patients with human papillomavirus-positive oral squamous cell carcinoma. For 
this reason, Radiation Therapy Oncology Group (RTOG) has initiated a phase III 
randomized study of radiotherapy with cisplatin or cetuximab in patients with human 
papilloma virus-associated oropharyngeal cancer (RTOG-1016). 
So, epidermal growth factor receptor, and p53 are also relevant markers that modify the 
prognostic effect of human papillomavirus and may help guide the development of targeted 
therapy in head and neck squamous cell carcinoma. 
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However, not all patients with human papillomavirus positive tumors respond well to 
therapy and the reasons for failure in some cases are not known (Maxwell et al., 2010). The 
variability of high risk human papillomavirus containing cell lines enhances our ability to 
study the role that human papillomavirus plays in head and neck squamous cell carcinoma 
development and response or resistance to therapy (Tang et al., 2011). Combination of 
several risk factors could explain this. A positive tobacco history in patients with human 
papillomavirus positive tumors may represent a distinct group of head and neck squamous 
cell carcinoma when all head and neck squamous cell carcinoma are divided by etiologic 
factors: human papillomavirus negative smokers, human papillomavirus positive never 
smokers, human papillomavirus positive ever smokers, etc… TPV status likely provided an 
additive and possibly synergistic effect with others risk factors (Tang et al., 2011). 
In addition, in the patient with metastatic head and neck carcinoma of unknown origin, the 
presence of human papillomavirus in a fine needle aspiration biopsy sample can be used to 
direct the search to the oropharynx (Zhang et al., 2008). 
All of this could lead to a new diagnosis and treatment algorithm (Figure 5). 
Others implications are the preventions actions: 
1. Screening studies have been performed in healthy adults using biopsy samples or less 
invasive saliva and oral lavage-based testing methods to identify human papillomavirus. 
These techniques revealed prevalence rate between 0-25% (Turner et al., 2011). 
Detection of high risk human papillomavirus DNA may help identify individuals, including 
those with: a) any genetic predisposition to acquire high risk human papillomavirus 
infection and/or b) a limited immunologic ability to eliminate the virus. Whether oral 
exfoliated high risk human papillomavirus status is predictive of cancer before invasion or 
progression in patients with head and neck squamous cell carcinoma is unknown.  
Quantitative measurement of salivary human papillomavirus16 DNA can be promise for 
surveillance and early detection of recurrence. Detection of high risk human papillomavirus 
in oral exfoliated cells may serve as clonal markers to monitor the presence of residual 
tumor after surgery or radiation, cancer recurrence, and progression (Pannone et al., 2011). 
A recent study (Turner et al., 2011) recruited patients and screened saliva samples for high 
risk human papillomavirus using quantitative polymerase chain reaction. They confirmed 
human papillomavirus16, but not human papillomavirus18 in a small subset of the healthy 
adult patients. These patients were female and minority (2.6%). 
2. Prophylactic vaccines that prevent persistent cervical human papillomavirus-16 
infections might be effective in preventing these cases of head-and-neck cancer as well, 
either indirectly by eliminating an anogenital source of virus or directly by protecting 
the oropharyngeal epithelium itself from infection (Psyrri & dimaio, 2008).  
In the U.S, two vaccines are currently available. The quadrivalent vaccine, Gardasil® (human 
papillomavirus4), protects against infection with human papillomavirus types -6, -11, -16, 
and 18. The second human papillomavirus vaccine, Cervarix® (human papillomavirus2), is a 
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bivalent vaccine that provides protection against human papillomavirus types -16 and -18 in 
(D´Souza & Dempsey, 2011). 
However, these vaccines do not alter the prognosis of established human papillomavirus 
infection. Therapeutic vaccines based on the viral oncogenes are still in the developmental 
stage, but they may eventually prove beneficial if used in association with conventional 
approaches for the management of advanced disease (Tran et al., 2007). 
 
Figure 5. Diagnosis and treatment algorithm 
6. Conclusion 
Emerging evidences suggest that human papillomavirus-associated head and neck 
squamous cell carcinoma is a separate subgroup and biologically distinct from classical head 
and neck squamous cell carcinoma. 
Human papillomavirus positive head and neck squamous cell carcinoma is typically 
found in the oropharynx and have been associated with younger patients who are less 
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likely to be smokers or drinkers and with improved response to therapy and overall 
survival (Harris et al., 2011). 
So, recognition that human papillomavirus has an etiologic role in head and neck squamous 
cell carcinoma has important implications for prognosis, treatment, disease prevention, and 
screening tests which are still being developed. Several authors have suggested that patients 
with human papillomavirus positive head and neck squamous cell carcinoma can be treated 
with chemo-radiotherapy or cetuximab-radiotherapy instead surgery. 
Although high risk human papillomavirus detection is of utmost importance in clinical 
setting of head and neck squamous cell carcinoma, there is no agreement about the “golden 
standard” considering the number of molecular methods or combinations available.  
There is evidence that detection of high risk human papillomavirus by consensus 
polymerase chain reaction alone is insufficient to accurately classify tumours, however, 
there is convincing evidence that the detection of p16 protein by immunohistochemistry can 
be used as a surrogate marker for the elaboration of oncogenic human papillomavirus 
proteins (Robinson et al., 2010). So, this is feasible as part of a routine diagnostic process 
using either a combination of p16 immunohistochemistry and in situ hybridization (Westra, 
2009) or p16 detection and consensus polymerase chain reaction (Smeets et al., 2007). 
Several studies have shown p16 expression status as a predictor of prognostic marker in 
head and neck squamous cell carcinoma, independent of human papillomavirus infection. 
In addition, epidermal growth factor receptor, and p53 are also relevant markers that 
modify the prognostic effect of human papillomavirus and may help guide the development 
of targeted therapy in head and neck squamous cell carcinoma. 
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